Financial Performance - For the year ended December 31, 2023, the revenue from continuing operations was RMB 2,992.7 million, an increase of 26.0% compared to RMB 2,375.0 million for the year ended December 31, 2022[1]. - The gross profit from continuing operations for the year ended December 31, 2023, was RMB 1,249.5 million, reflecting a 34.8% increase from RMB 927.2 million for the year ended December 31, 2022[1]. - The profit attributable to owners of the company for the year ended December 31, 2023, was RMB 363.8 million, up 25.1% from RMB 290.8 million for the year ended December 31, 2022[1]. - The adjusted EBITDA from continuing operations for the year ended December 31, 2023, was RMB 1,072.4 million, representing a 30.9% increase from RMB 819.1 million for the year ended December 31, 2022[1]. - The operating profit for the year ended December 31, 2023, was RMB 656.9 million, compared to RMB 431.7 million for the year ended December 31, 2022[20]. - The net profit from continuing operations for the year ended December 31, 2023, was RMB 401.975 million, up from RMB 243.149 million for the year ended December 31, 2022[20]. - The company's net profit for the year ended December 31, 2023, was RMB 401,975 thousand, representing a 50.4% increase from RMB 267,187 thousand in 2022[25]. - Total comprehensive income for the year was RMB 402,350 thousand, up from RMB 268,912 thousand in the previous year, marking a growth of 49.5%[25]. Revenue Breakdown - Total revenue for the year ended December 31, 2023, was RMB 2,992,689,000, with a segment profit of RMB 868,925,000[60]. - The comprehensive hospital segment generated revenue of RMB 627,659,000, while the health check center segment contributed RMB 2,386,006,000[60]. - The health check-up business revenue reached RMB 2,386.0 million in 2023, a 35.2% increase from RMB 1,765.4 million in 2022, driven by a 31.8% growth in the number of check-ups and a 2.6% increase in average spending per person[137]. - Outpatient service revenue was RMB 84,198 thousand, down 4.3% from RMB 88,122 thousand in 2022[100]. - Inpatient service revenue increased to RMB 256,107 thousand, up 11.3% from RMB 230,269 thousand in 2022[100]. Assets and Liabilities - As of December 31, 2023, total assets amounted to RMB 4,637,755,000, with total liabilities of RMB 3,523,710,000[60]. - The company's equity attributable to owners increased to RMB 1,114,045 thousand from RMB 904,826 thousand, marking a growth of 23.1%[44]. - The total liabilities decreased to RMB 3,523,710 thousand from RMB 3,662,032 thousand, indicating a reduction of 3.8%[44]. - The financial liabilities of the group were RMB 3,269.1 million, a decrease from RMB 3,426.6 million as of December 31, 2022[8]. - Total assets as of December 31, 2023, amounted to RMB 4,637,755 thousand, a slight increase from RMB 4,566,858 thousand in 2022[34]. Employee and Operational Metrics - The number of employees in the group as of December 31, 2023, was 9,413, an increase from 8,737 as of December 31, 2022[16]. - The group operated 79 health check-up centers nationwide as of December 31, 2023, with 72 centers already in operation, covering 29 cities[158]. - The number of outpatient visits in the first nine months of 2023 reached 5.11 billion, a year-on-year increase of 6%[107]. - The nursing home operated at an occupancy rate of 89.6% as of December 31, 2023, down from 94.2% in 2022[110]. Cost and Expenses - The income tax expense for continuing operations in 2023 was RMB 143.7 million, compared to RMB 84.0 million in 2022, primarily due to the increase in profit from continuing operations[12]. - The group reported administrative expenses of RMB 223,845,000 and net impairment losses on financial assets of RMB 9,042,000[60]. - Employee benefit expenses increased to RMB 1,098,021, up from RMB 901,209 in 2022, reflecting a growth of approximately 21.8%[121]. - The sales cost for the health check business rose by 29.0% to RMB 1,260.5 million in 2023, driven by an increase in the number of health check visits[166]. Strategic Initiatives - The company established a Shanghai medical service center, enhancing its market expansion efforts by connecting with over 150 top doctors from 20 hospitals[129]. - The company’s collaboration with Fudan University hospitals focuses on oncology, indicating a strategic move towards specialized medical services[130]. - The group plans to continue focusing on high-end health check-up services and expand its presence in key markets such as Shanghai, Beijing, Jiangsu, the Greater Bay Area, and Zhejiang[158]. - The company implemented a "patient satisfaction first" action plan to enhance patient experience and satisfaction[163]. - The company aims to establish itself as one of the three major medical centers in Nantong by creating a comprehensive hospital with a focus on high-quality specialty development[163]. Dividends and Shareholder Returns - The group declared a special dividend of HKD 0.13 per share, totaling HKD 206,742,000 (approximately RMB 187,904,000)[153]. - Basic and diluted earnings per share attributable to owners of the company from continuing operations for the year ended December 31, 2023, was RMB 0.23, compared to RMB 0.18 for the year ended December 31, 2022[23]. - Basic and diluted earnings per share increased to RMB 0.23 from RMB 0.15, indicating a growth of 53.3%[31].
瑞慈医疗(01526) - 2023 - 年度业绩